Viragen, Inc., based in Plantation, Florida, is a biotechnology company focused on the research, development, and commercialization of protein-based drugs. Their product lineup includes natural human alpha interferon (Multiferon), monoclonal antibodies, and an immune peptide drug, all designed to treat a wide range of viral and malignant diseases. Viragen aims to leverage its expertise in protein-based therapeutics to address significant medical challenges in the healthcare market.
Viragen has made substantial strides in the biotechnology sector, particularly with the development and commercialization of Multiferon, which has shown promise in treating various conditions. The company's innovative approach to using natural and recombinant proteins has positioned it as a key player in the fight against viral and malignant diseases. Through its pioneering work, Viragen continues to contribute to advancements in medical treatments, improving patient outcomes and expanding therapeutic options.